|Last Price$73.59||Day Change (%)5.01%|
|Open Price$72.31||Day Change ($)3.51|
|Day Range70.62–73.68||52-Week Range35.68–76.11|
As of Thu 12/19/2013 07:15 AM EST | USD
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
Research and Markets: Global Liver Fibrosis Clinical Trials Report - H2 2013 Review
Research and Markets: Liver Transplantation Global Clinical Trials Review, H2, 2013 Includes an Overview of the Trial Numbers and their Recruitment Status
Our top managers continue to find attractive buying opportunities in wide-moat firms.
These three outstanding leaders have demonstrated sound stewardship practices for their firms' shareholders.